博客來Cancer and the Profit Machine is not a book about miracle cures or fringe theories. It is an institutional investigation into how modern cancer treatment evolved into a system optimized for revenue, chronic management, and narrative control-often at the expense of prevention and accountability.
Over decades, cancer has been reframed from a preventable public-health failure into a permanent medical condition requiring endless intervention. This book examines how that shift occurred, tracing the historical foundations of chemotherapy and radiation, the economics of pharmaceutical development, and the regulatory structures that tolerate known carcinogenic exposure while prioritizing downstream treatment. It explores why incidence remains stubbornly high even as treatment costs and complexity accelerate.
Drawing on peer-reviewed research, government data, legal standards, and historical precedent, the book analyzes cancer not only as a biological disease, but as an institutional outcome shaped by incentives, liability frameworks, and information management. It addresses environmental, metabolic, inflammatory, and infectious contributors without speculation, while also examining why certain research pathways-especially prevention and non-proprietary approaches-remain marginalized.
The analysis maintains skepticism in all directions. It questions the limits of mainstream oncology without promoting simplistic ＂cures,＂ and it examines alternative hypotheses without abandoning scientific rigor. Throughout, the focus remains on structure: how systems reward treatment volume over incidence reduction, how uncertainty is managed rather than resolved, and how responsibility dissolves across institutions and generations.
Cancer and the Profit Machine is written for intelligent general readers, patients, professionals, and skeptics who sense that something essential has been left unexamined. It does not tell readers what to think. It documents what has been normalized-and asks what it would mean to stop accepting it.
